baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

ROCHE I/ CH0012032113 /

2024-07-10 2:57:04 PM	Chg. +1.60	Volume	Bid3:01:39 PM	Ask3:01:39 PM	Market Capitalization	Dividend Y.	P/E Ratio
273.60CHF	+0.59%	9,392 Turnover: 2.56 mill.	273.60Bid Size: 194	273.80Ask Size: 104	229.04 bill.CHF	3.47%	19.03

Newsfile Corp 2:30 PM First Phosphate confirme le plus long intervalle à haute teneur à ce jour de 8,9 % de phosphate igné...

GlobeNewswire 06-27 Arch Biopartners Announces GMP Manufacturing of Cilastatin Drug Product

GlobeNewswire 06-18 Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for ...

GlobeNewswire 06-14 LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon...

GlobeNewswire 06-11 Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D ...

TeleTrader 05-27 Roche shuffles its executive committee

TeleTrader 05-16 Roche notes progress in obesity drug trial

GlobeNewswire 05-09 US Neurologists Report Route of Administration as a Critical Factor when Evaluating Future Parkinson...

GlobeNewswire 05-07 Enable Injections Expands Strategic Partnership with Roche

TeleTrader 04-24 Roche's logs 14.4 billion Swiss francs in Q1 sales

GlobeNewswire 04-03 UHN Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Inju...

GlobeNewswire 04-02 Arch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting C...

GlobeNewswire 04-01 AssetMark Honors Financial Advisors with Community Inspiration Award

GlobeNewswire 03-22 HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highl...

GlobeNewswire 03-14 Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides C...

GlobeNewswire 02-26 Codexis Enters Exclusive Licensing Agreement for Newly Engineered Double-Stranded DNA Ligase with Ro...

GlobeNewswire 02-21 REPARE ALERT: Bragar Eagel & Squire, P.C. is Investigating Repare Therapeutics Inc. on Behalf of Rep...

GlobeNewswire 02-13 Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Busine...

GlobeNewswire 02-08 Accumulus Synergy Launches Highly Anticipated Cloud-Based Platform

TeleTrader 02-01 Roche's 2023 sales increase 1% to 58.7B Swiss francs

GlobeNewswire 01-30 COUR Pharmaceuticals Secures $105 Million in Series A Financing Co-Led by Lumira Ventures and Alpha ...

GlobeNewswire 01-29 Carmot Therapeutics Announces Completion of Acquisition by Roche

GlobeNewswire 01-03 US Neurologists Optimistic Regarding the Huntington’s Disease Treatment Pipeline, Emphasizing Haltin...

GlobeNewswire 01-03 Arch Biopartners Receives Approval from the Turkish Ministry of Health to Proceed with Phase II Tria...

GlobeNewswire 2023-12-29 LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to Roche

ROCHE I/ CH0012032113 /

If you wish to receive reply to your feedback, please provide your email address.